Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)

Figures & data

Table 1 Patient-related risk factors for emesis following chemotherapy

Major factors	Minor factors
Female	History of motion sickness
Age <50 years	Emesis during past pregnancy
History of low prior chronic alcohol intake (<1 ounce of alcohol/day)
History of previous chemotherapy-induced emesis

Table 2 5-HT₃ receptor antagonists’ binding affinity and plasma half-life

Drug	pKi [−log(Ki)]	Half-life (hours)
Palonosetron	10.45	40
Ondansetron	8.39	4
Granisetron	8.91	9
Dolasetrona	7.60	7.3

Notes:

a Half-life reported for hydrodolasetron, the active metabolite of dolasetron.

Figure 1 Profile of Netupitant.